Document is current
Any future updates will be listed below
-
Authors
Benitez, Alain J.
Tanes, Ceylan
Friedman, Elliot S.
Zackular, Joseph P.
Ford, Eileen
Gerber, Jeffrey S.
DeRusso, Patricia A.
Kelly, Andrea
Li, Hongzhe
Elovitz, Michal A.
Wu, Gary D.
Zemel, Babette
Bittinger, Kyle
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (KL2TR001879)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK107565, R01DK107565, R01DK107565, R01DK107565, R01DK107565, R01DK107565, R01DK107565, R01DK107565, R01DK107565, R01DK107565, R01DK107565)
National Institute of General Medical Sciences (R35GM138369)
NIH National Center for Research Resources Clinical and Translational Science Program (UL1TR001878)
American Beverage Foundation for a Healthy America (unrestricted donation)
- License Information
-
More Information
Article History
Received: 5 April 2024
Accepted: 5 December 2024
First Online: 24 January 2025
Declarations
:
: The study was approved by the Institutional Review Board (IRB) at Children’s Hospital of Philadelphia (IRB 14–010833).
: The IGram study enrolled pregnant African American mothers and their newborn infants. The purpose of the research study was to learn more about the bacteria normally living in the child’s gut, how it is transferred from mother to child, and whether it affects the child’s growth in the first 3 years of life. The IGRAM data used in this publication are consistent with the stated purpose of the research. The Institutional Review Board-approved consent documents included language that allowed participants to indicate whether they would like to have their information included in future research. Subjects may participate in the original research without their information (even if de-identified) being included in future research.
: Dr Elovitz receives salary support from NIAID, NICHD and NINR. She serves as a consultant with equity for Mirvie. No other disclosures were reported.
